引用本文:田 申,伍 娟(综述),孔令泉,吴凯南(审校).关注乳腺癌伴随疾病全方位管理之非酒精性脂肪性肝病的管理[J].中国临床新医学,2020,13(8):836-840.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 29次   下载 35 本文二维码信息
码上扫一扫!
分享到: 微信 更多
关注乳腺癌伴随疾病全方位管理之非酒精性脂肪性肝病的管理
田 申,伍 娟(综述),孔令泉,吴凯南(审校)
400016 重庆,重庆医科大学附属第一医院内分泌乳腺外科
摘要:
[摘要] 非酒精性脂肪性肝病在乳腺癌患者化疗及内分泌治疗期间有较高的发生率,它是患者肝功能损伤或肝酶异常的常见原因,并影响乳腺癌患者的治疗和预后,但其防治尚未引起足够的重视。该文将系统阐述乳腺癌患者辅助治疗期间非酒精性脂肪性肝病的管理与防治,以提高对其认识,并进一步改善乳腺癌患者的生存质量和预后。
关键词:  乳腺癌  乳腺癌伴随疾病  非酒精性脂肪肝  乳腺肿瘤肝病学  代谢相关脂肪性肝病
DOI:10.3969/j.issn.1674-3806.2020.08.26
分类号:R 736;R 657
基金项目:
Strengthening the comprehensive management of concomitant diseases of breast cancer: non-alcoholic fatty liver disease
TIAN Shen, WU Juan, KONG Ling-quan, et al.
Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Abstract:
[Abstract] Non-alcoholic fatty liver disease(NAFLD) has a high incidence in breast cancer patients during chemotherapy and endocrine therapy. NAFLD is a common case of hepatic dysfunction and abnormal liver enzymes, and therefore affects the therapy and prognosis of breast cancer patients. However, the prevention and treatment of NAFLD has not attracted enough attention. In this paper, we systematically review the management, prevention and treatment of NAFLD in breast cancer patients during adjuvant therapy to raise awareness of NAFLD and further improve the quality of life and prognosis of breast cancer patients.
Key words:  Breast cancer  Concomitant diseases of breast cancer(CDBC)  Non-alcoholic fatty liver disease(NAFLD)  Breast oncohepatology  Metabolic associated fatty liver disease